|
US1394233A
(en)
|
|
1921-10-18 |
|
Arthur stoll |
|
US2438259A
(en)
|
|
1948-03-23 |
|
D-lysergic acid diethyl amide |
|
US2774763A
(en)
|
|
1956-12-18 |
|
Preparation of amides of lysergic age |
|
US3085092A
(en)
|
|
1963-04-09 |
|
Preparation of lysergic acid deriva- |
|
US2090429A
(en)
|
|
1937-08-17 |
|
Lysergic acid hydkazide and a |
|
US2447214A
(en)
|
|
1948-08-17 |
|
Hoocxchoxxchoxxcooh |
|
US2090430A
(en)
|
|
1937-08-17 |
|
Lysergic acid amides and process for |
|
US2265207A
(en)
|
|
1941-12-09 |
|
D-lysergic acid - d - l-bjtdroxybutyl |
|
GB579484A
(en)
|
1943-04-30 |
1946-08-06 |
Sandoz Ltd |
Process for the preparation of diethylamide of d-lysergic acid
|
|
US2809920A
(en)
|
1953-04-10 |
1957-10-15 |
Saul & Co |
Process for the preparation of ergotamine, ergotaminine and ergometrine by saprophytic culture of ergot (claviceps purpurea [fr] tul.) in vitro and isolation of the alkaloids thus produced
|
|
US2796419A
(en)
|
1954-09-27 |
1957-06-18 |
Lilly Co Eli |
Lysergic acid, intermediates and preparation
|
|
US2736728A
(en)
|
1954-12-06 |
1956-02-28 |
Lilly Co Eli |
Preparation of lysergic acid amides
|
|
US2997470A
(en)
|
1956-03-05 |
1961-08-22 |
Lilly Co Eli |
Lysergic acid amides
|
|
US3038840A
(en)
|
1959-07-07 |
1962-06-12 |
Farmaceutici Italia |
Process for the production of alkaloid derivatives of lysergic acid
|
|
FR1338023A
(fr)
|
1962-10-15 |
1963-09-20 |
Farmaceutici Italia |
Nouveau procédé de préparation d'amides d'acide lysergique, substituées ou non
|
|
US3239530A
(en)
|
1964-01-13 |
1966-03-08 |
Sandoz Ltd |
Process for lysergic acid hydrazides
|
|
CH535236A
(de)
|
1970-06-19 |
1973-03-31 |
Sandoz Ag |
Verfahren zur Herstellung neuer reaktionsträger Lysergsäurederivate
|
|
GB1548022A
(en)
|
1976-10-06 |
1979-07-04 |
Wyeth John & Brother Ltd |
Pharmaceutial dosage forms
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4925678A
(en)
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
US5167616A
(en)
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
US5225182A
(en)
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
US5738875A
(en)
|
1994-10-28 |
1998-04-14 |
R.P. Scherer Corporation |
Process for preparing solid pharmaceutical dosage forms
|
|
US6063908A
(en)
|
1996-07-02 |
2000-05-16 |
Roche Diagnostics Corporation |
Reagents for lysergic acid diethylamide immunoassay
|
|
US20020028942A1
(en)
|
1997-01-15 |
2002-03-07 |
Jacewicz Victor Witold |
Novel process and compound
|
|
UA57859C2
(uk)
|
1998-10-14 |
2003-07-15 |
Авентіс Фармасьютікалз Інк. |
СКЛАДНІ ЕФІРИ (+)-АЛЬФА-(2,3-ДИМЕТОКСИФЕНІЛ)-1-[2-(4-ФТОРФЕНІЛ)ЕТИЛ]-4-ПІПЕРИДИНМЕТАНОЛУ, СПОСІБ ЇХ ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ІНГІБУВАННЯ ДІЇ СЕРОТОНІНУ НА 5HT<sub>2A</sub> РЕЦЕПТОР, СПОСІБ ЛІКУВАННЯ
|
|
GB9908014D0
(en)
|
1999-04-08 |
1999-06-02 |
Scherer Corp R P |
Pharmaceutical compositions
|
|
EP1248832A4
(en)
|
2000-01-21 |
2004-07-07 |
Variagenics Inc |
IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
|
|
US6794496B2
(en)
|
2000-04-07 |
2004-09-21 |
Roche Diagnostics Corporation |
Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
|
|
WO2002069933A1
(fr)
*
|
2001-03-06 |
2002-09-12 |
Kyowa Hakko Kogyo Co., Ltd. |
Comprimés à délitement rapide dans la bouche
|
|
DE60239042D1
(de)
|
2001-12-20 |
2011-03-10 |
Randox Lab Ltd |
Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD
|
|
GB0210397D0
(en)
*
|
2002-05-07 |
2002-06-12 |
Ferring Bv |
Pharmaceutical formulations
|
|
US8401801B2
(en)
|
2003-02-20 |
2013-03-19 |
Mayo Foundation For Medical Education And Research |
Methods for selecting medications
|
|
US8012505B2
(en)
|
2003-02-28 |
2011-09-06 |
Alk-Abello A/S |
Dosage form having a saccharide matrix
|
|
WO2005115473A2
(en)
|
2004-05-24 |
2005-12-08 |
Nutrinia Ltd. |
Nutritional food and feed, composition, processing and method of use
|
|
EP1781272B1
(en)
|
2004-07-24 |
2017-09-06 |
Laboratorios Del Dr. Esteve, S.A. |
Use of compounds active on the sigma receptor for the treatment of mechanical allodynia
|
|
US20060039890A1
(en)
|
2004-08-20 |
2006-02-23 |
Renshaw Perry F |
Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
|
|
JP2006124282A
(ja)
|
2004-10-26 |
2006-05-18 |
Central Glass Co Ltd |
3,3,3−トリフルオロプロピオン酸の製造方法
|
|
US20060167481A1
(en)
|
2005-01-25 |
2006-07-27 |
Esophyx, Inc. |
Slitted tissue fixation devices and assemblies for deploying the same
|
|
US20060223998A1
(en)
|
2005-03-30 |
2006-10-05 |
Fang-Jie Zhang |
Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
CA2650498A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Rubicon Research Private Limited |
Orally disintegrating tablets
|
|
WO2008116024A2
(en)
|
2007-03-19 |
2008-09-25 |
Acadia Pharmaceuticals Inc. |
Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
|
|
CN101686942B
(zh)
|
2007-06-27 |
2012-09-26 |
韩美药品株式会社 |
用于快速制备用于口服的崩解剂的方法及其产品
|
|
JP5450435B2
(ja)
|
2007-11-30 |
2014-03-26 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
ヘテロアリールで置換されたピペリジン類
|
|
US9642819B2
(en)
|
2008-07-10 |
2017-05-09 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical |
Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
|
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
|
BRPI0918623A2
(pt)
|
2008-09-17 |
2015-12-01 |
Hannover Med Hochschule |
métodos e kits para tratar distúrbios de cefaleia em grupo
|
|
ES2607209T3
(es)
|
2009-02-06 |
2017-03-29 |
Egalet Ltd. |
Composiciones farmacéuticas resistentes al abuso
|
|
US10548839B2
(en)
*
|
2010-03-16 |
2020-02-04 |
Wei Tian |
Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
WO2012058769A1
(en)
|
2010-11-03 |
2012-05-10 |
Mcmaster University |
Method of treating mucosal inflammation
|
|
WO2014059197A1
(en)
|
2012-10-10 |
2014-04-17 |
Henkin Robert I |
Methods and compositions for diagnosing and treating hyposmia
|
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
|
US20170253928A1
(en)
|
2013-03-15 |
2017-09-07 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
|
US20140274764A1
(en)
|
2013-03-15 |
2014-09-18 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
|
US10118006B2
(en)
|
2014-06-30 |
2018-11-06 |
Syqe Medical Ltd. |
Methods, devices and systems for pulmonary delivery of active agents
|
|
US10098854B2
(en)
|
2014-08-13 |
2018-10-16 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
EP2990029A1
(en)
|
2014-08-29 |
2016-03-02 |
Sandoz Ag |
Pharmaceutical compositions comprising Canagliflozin
|
|
ES2985064T3
(es)
|
2015-01-28 |
2024-11-04 |
Univ Duke |
Composición que comprende metilfenidato y ondansetrón para su uso en trastornos relacionados con la toxicomanía
|
|
US20180105876A1
(en)
|
2015-04-18 |
2018-04-19 |
Baycrest Technology Pty Ltd |
Medication dosing report
|
|
DK3334709T3
(da)
|
2015-08-12 |
2025-02-03 |
Incyte Holdings Corp |
Salte af en lsd1-hæmmer
|
|
WO2017066488A1
(en)
|
2015-10-13 |
2017-04-20 |
Charleston Laboratories, Inc. |
Treating pain using a composition comprising an opioid and an antiemetic
|
|
US20210069170A1
(en)
|
2016-07-23 |
2021-03-11 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
US20200222656A1
(en)
|
2016-10-18 |
2020-07-16 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
NL2018190B1
(en)
|
2017-01-18 |
2018-07-26 |
Procare Beheer B V |
Psilocybin or psilocin in combination with cannabinoid
|
|
US11974984B2
(en)
|
2017-02-09 |
2024-05-07 |
Caamtech, Inc. |
Compositions and methods comprising a combination of serotonergic drugs
|
|
US20190142851A1
(en)
|
2017-11-16 |
2019-05-16 |
CaaMTech, LLC |
Compositions comprising a psilocybin derivative and a cannabinoid
|
|
CA3057994A1
(en)
|
2017-03-30 |
2018-10-04 |
Ojai Energetics Pbc |
A unit dose or mixture comprising carboxylated and decarboxylated cannabinoids
|
|
US20200147038A1
(en)
|
2017-04-20 |
2020-05-14 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
US11471415B2
(en)
|
2017-10-10 |
2022-10-18 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation and methods of treatment
|
|
WO2019079742A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES
|
|
US11723894B2
(en)
|
2017-10-26 |
2023-08-15 |
Terran Biosciences, Inc. |
Combination product for the treatment of neurological and/or psychiatric disorders
|
|
EP3707275A4
(en)
|
2017-11-07 |
2021-11-10 |
Medreleaf Corp. |
DOSAGE AND VARIETY RECOMMENDATIONS FOR THE TREATMENT OF DISEASES USING CANNABIS
|
|
US11367103B2
(en)
|
2020-03-02 |
2022-06-21 |
Yieldmo, Inc. |
Method for modeling digital advertisement consumption
|
|
EP3813810A4
(en)
|
2018-06-21 |
2022-03-30 |
Robert John Petcavich |
METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
|
|
WO2020024977A1
(zh)
|
2018-08-01 |
2020-02-06 |
陕西麦科奥特科技有限公司 |
用于治疗神经系统疾病的化合物及其应用
|
|
MX2021009037A
(es)
|
2019-01-30 |
2021-10-13 |
Diamond Therapeutics Inc |
Composiciones y metodos para el manejo de trastornos.
|
|
HUE066828T2
(hu)
|
2019-02-22 |
2024-09-28 |
Gh Res Ireland Limited |
5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
|
|
US12616706B2
(en)
|
2019-03-07 |
2026-05-05 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
KR20220008824A
(ko)
|
2019-04-17 |
2022-01-21 |
컴퍼스 패쓰파인더 리미티드 |
실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
|
|
WO2020216832A1
(en)
|
2019-04-24 |
2020-10-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the response of antipsychotic drugs
|
|
WO2020232255A1
(en)
|
2019-05-14 |
2020-11-19 |
The Scripps Research Institute |
Compounds for the treatment of neurodegenerative and metabolic disorders
|
|
WO2021003467A1
(en)
|
2019-07-04 |
2021-01-07 |
Sw Holdings, Inc. |
Metered dosing compositions and methods of use of psychedelic compounds
|
|
US20210015738A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Concept Matrix Solutions |
Oral dissolvable film containing psychedelic compound
|
|
GB201911024D0
(en)
|
2019-08-01 |
2019-09-18 |
Beckley Found |
Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
|
|
WO2021030571A1
(en)
|
2019-08-13 |
2021-02-18 |
University Of Maryland, Baltimore |
Methods of treating psychological and brain disorders
|
|
US11246860B2
(en)
|
2019-11-07 |
2022-02-15 |
Lophora ApS |
5-HT2A agonists for use in treatment of depression
|
|
IL295671A
(en)
|
2020-02-28 |
2022-10-01 |
Universit?Tsspital Basel |
Controlling effects after 5ht2a agonists administration
|
|
GB202003059D0
(en)
|
2020-03-03 |
2020-04-15 |
Beckley Found |
Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
|
|
CN115916173A
(zh)
|
2020-04-13 |
2023-04-04 |
巴塞尔大学医院 |
Lsd剂量鉴定
|
|
CA3173048A1
(en)
|
2020-04-16 |
2021-10-21 |
Fotios M. Plakogiannis |
Transdermal micro-dosing delivery of psychedelics derivatives
|
|
EP4142693A1
(en)
|
2020-05-01 |
2023-03-08 |
Emergex USA Corporation |
Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
|
|
AU2021267101B2
(en)
|
2020-05-05 |
2024-03-28 |
Universitätsspital Basel |
MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
|
|
WO2021243461A1
(en)
|
2020-06-04 |
2021-12-09 |
Neonmind Biosciences Inc. |
Use of lsd, esa, or dmt for weight loss.
|
|
AU2021292943B2
(en)
|
2020-06-15 |
2024-04-04 |
Universitätsspital Basel |
MDMA response prediction
|
|
EP4167992A1
(en)
|
2020-06-22 |
2023-04-26 |
University of Zürich |
Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
|
|
US20210407643A1
(en)
|
2020-06-25 |
2021-12-30 |
Greenway Dna Inc. |
Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
|
|
WO2022008627A2
(en)
|
2020-07-07 |
2022-01-13 |
Compass Pathfinder Limited |
Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
|
|
EP4188382A4
(en)
|
2020-07-29 |
2024-08-14 |
The Royal Institution for the Advancement of Learning / McGill University |
Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions
|
|
WO2022023812A1
(en)
|
2020-07-29 |
2022-02-03 |
Diamond Therapeutics Inc. |
Extended release 5-ht receptor agonists for neurological conditions
|
|
WO2022030571A1
(ja)
|
2020-08-06 |
2022-02-10 |
株式会社一志精工電機 |
金型構造、プレス加工装置、およびプレス加工方法
|
|
DE202020105085U1
(de)
|
2020-09-03 |
2020-11-30 |
Sophie-Charlotte Adler |
Therapiemethode in Kombination mit psychoaktiver Zusammensetzung
|
|
EP4222501A1
(en)
|
2020-10-24 |
2023-08-09 |
Universitätsspital Basel |
Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma
|
|
WO2022107095A1
(en)
|
2020-11-22 |
2022-05-27 |
Havn Life Sciences Inc. |
Methods and compositions for treating pain with 2-bromo-lysergic acid diethylamide and thymoquinone
|
|
WO2022115796A1
(en)
|
2020-11-30 |
2022-06-02 |
Wesana Health Inc. |
Compositions and methods for treating neurological conditions
|
|
WO2022120289A1
(en)
|
2020-12-02 |
2022-06-09 |
The Johns Hopkins University |
Restoration of motor function post-neurological injury using psychedelics
|
|
EP4126857A1
(en)
|
2021-01-15 |
2023-02-08 |
Beckley Psytech Limited |
Ergoline analogues
|
|
US20220273628A1
(en)
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
BR112023017866A2
(pt)
|
2021-03-06 |
2023-10-10 |
Univ Basel |
Método de dosagem de lsd no tratamento de pacientes, método para determinar uma dose preferida de lsd e método para determinar uma dose de lsd com base na avaliação da presença de inibidores de cyp2d6
|
|
KR20240006525A
(ko)
|
2021-03-31 |
2024-01-15 |
라이프 씨에이치엔지 엘엘씨 |
환각제의 치료적 투여를 위한 경피 시스템, 제제 및 방법
|
|
WO2022221942A1
(en)
|
2021-04-19 |
2022-10-27 |
Betterlife Pharma Inc. |
Prevention of drug diversion
|
|
IL307880A
(en)
|
2021-04-23 |
2023-12-01 |
Gilgamesh Pharmaceuticals Inc |
New ergolines and methods for treating mood disorders
|
|
US20230116703A1
(en)
|
2021-04-23 |
2023-04-13 |
Gilgamesh Pharmaceuticals, Inc. |
Novel ergolines and methods of treating mood disorders
|
|
EP4329759A4
(en)
|
2021-04-30 |
2025-07-16 |
Mind Medicine Inc |
CRYSTALLINE FORMS OF LSD SALTS
|
|
US20220362237A1
(en)
|
2021-05-03 |
2022-11-17 |
Mind Medicine, Inc. |
Psychedelics for treatment of pain
|
|
EP4333979A4
(en)
|
2021-05-03 |
2025-01-15 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
US20220347195A1
(en)
|
2021-05-03 |
2022-11-03 |
Mind Medicine, Inc. |
Psychedelics for treatment of pain
|
|
US12611399B2
(en)
|
2021-05-04 |
2026-04-28 |
Definium Therapeutics US, Inc. |
Movement disorders
|
|
US20230301985A1
(en)
|
2021-05-04 |
2023-09-28 |
Mind Medicine, Inc. |
Movement disorders
|
|
WO2022246572A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Mindset Pharma Inc. |
Hallucinogen-fatty acid combination
|
|
WO2022261058A1
(en)
|
2021-06-07 |
2022-12-15 |
University Of Mississippi |
Methods for the pulsed delivery of bioactive agents
|
|
WO2022265878A1
(en)
|
2021-06-14 |
2022-12-22 |
Mind Medicine, Inc. |
Controlling effects after 5ht2a agonists administration
|
|
WO2023283386A2
(en)
|
2021-07-07 |
2023-01-12 |
Arcadia Medicine, Inc. |
Safer psychoactive compositions
|
|
US20230059204A1
(en)
|
2021-08-03 |
2023-02-23 |
Pike Therapeutics, Inc. |
Transdermal micro-dosing delivery of pharmaceutical agents
|
|
WO2023012524A2
(en)
|
2021-08-03 |
2023-02-09 |
Universitatsspital Basel |
Lsd and psilocybin dose equivalence determination
|
|
US20230064429A1
(en)
|
2021-08-19 |
2023-03-02 |
Mind Medicine, Inc. |
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
|
|
WO2023043870A1
(en)
|
2021-09-15 |
2023-03-23 |
Eleusis Therapeutics Us, Inc. |
Chewing gum formulation of lsd and methods of use thereof
|
|
US20230219955A1
(en)
|
2021-09-20 |
2023-07-13 |
Betterlife Pharma Inc. |
Lsd derivatives, synthesis & method for treatment of diseases and disorders
|
|
WO2023107966A1
(en)
|
2021-12-06 |
2023-06-15 |
Terran Biosciences, Inc. |
Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
|
|
WO2023108277A1
(en)
|
2021-12-14 |
2023-06-22 |
Agile Pharmaceuticals Solutions Inc. |
Cannabinoid and psychedelic formulations comprising hydrotropic agents
|
|
EP4448518A4
(en)
|
2021-12-16 |
2025-12-17 |
Terran Biosciences Inc |
ISOTOPICALLY ENRICHED ANALOYS OF 2-BROM-LSD, LSD, ALD-52 AND 1P-LSD
|
|
WO2023114529A2
(en)
|
2021-12-17 |
2023-06-22 |
Bennes, Inc. |
Pharmacoactive formulations for delivery of psychedelic compounds
|
|
EP4499109A1
(en)
|
2022-03-25 |
2025-02-05 |
Ojai Energetics PBC |
Psychedelic compositions and methods for forming the same
|
|
US20250295611A1
(en)
|
2022-04-27 |
2025-09-25 |
Tessellate Therapeutics Inc. |
Methods of treating 5ht2a receptor-mediated conditions
|
|
US20230346645A1
(en)
|
2022-05-01 |
2023-11-02 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
CN119923261A
(zh)
|
2022-06-20 |
2025-05-02 |
思维医学股份有限公司 |
具有改良的lsd样作用的麦角酸衍生物
|
|
US20260034058A1
(en)
|
2022-08-09 |
2026-02-05 |
Vitalmelt Ltd. |
Freeze-dried bite with single dose psychedelic
|
|
JP2026515993A
(ja)
|
2023-05-04 |
2026-05-19 |
ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド |
新規エルゴリン及び気分障害を処置する方法
|
|
WO2024238035A1
(en)
|
2023-05-16 |
2024-11-21 |
Mind Medicine, Inc. |
Movement disorders
|
|
WO2024263978A1
(en)
|
2023-06-22 |
2024-12-26 |
Mind Medicine, Inc. |
Allyl- and propargylamine-type phenethylamines and tryptamines for treating medical disorders
|
|
WO2025128594A1
(en)
|
2023-12-11 |
2025-06-19 |
Mind Medicine, Inc. |
Methods of treating generalized anxiety disorder
|